Nephrology · Medical Literature
FDA Adds Kidney Injury Warning to OTC Weight-Loss Drug Orlistat
Abstract
The US Food and Drug Administration (FDA) approved labeling changes for the over-the-counter (OTC) weight-loss drug orlistat to warn of acute kidney injury risks.
Clinical relevance
On June 10, 2026, the FDA updated the Drug Facts Label for OTC orlistat (alli 60 mg) to include explicit warnings about acute kidney injury (AKI), hyperoxaluria, calcium oxalate nephrolithiasis, and oxalate nephropathy — renal risks that were previously underappreciated by both patients and non-nephrology clinicians. This action is particularly timely given that orlistat remains the only FDA-approved OTC weight-loss agent and is increasingly sought by cost-conscious patients who cannot access or afford GLP-1 receptor agonists. Because patients may self-initiate OTC orlistat without any clinician encounter, nephrologists and primary care physicians must now proactively counsel at-risk populations — especially those with pre-existing CKD, nephrolithiasis, or hyperoxaluria — before or during use.
Key findings
1. The FDA identified 12 confirmed cases of serious kidney complications associated with OTC orlistat (alli 60 mg) via the FDA Adverse Event Monitoring System (AEMS) and medical literature review spanning alli's approval date of February 9, 2007, through December 31, 2023. 2. Among the 12 cases, the spectrum of renal injury included: 8 cases of AKI alone, 2 cases of AKI with oxalate nephropathy, and 2 cases of hyperoxaluria with calcium oxalate nephrolithiasis. 3. Severity was substantial: 8 of 12 patients (67%) required hospitalization and 5 of 12 (42%) required dialysis; 7 patients demonstrated clinical improvement, while outcomes were unreported in 4 cases. 4. The median patient age was 61 years (range 36–76 years), with a slight female predominance (7F:5M); median exposure duration prior to kidney injury was 2.5 months (range 0.7–17 months). 5. Available dosing data (4 patients) confirmed injury occurred at both the OTC dose (60 mg TID) and the prescription dose (120 mg TID), indicating the renal risk does not appear to be dose-dependent. 6. The labeling change harmonizes the kidney injury warning across all FDA-approved orlistat formulations (OTC alli 60 mg and prescription Xenical 120 mg), correcting a prior regulatory inconsistency in which the higher-strength product carried warnings not present on the OTC label. Note: No formal RCT-derived effect sizes, confidence intervals, p-values, or NNT/NNH were reported in the FDA safety communication; the evidence base is derived from pharmacovigilance (AEMS case series) and published case reports.
Practice implications
Clinicians counseling patients on weight management should explicitly screen for a history of CKD, nephrolithiasis, or hyperoxaluria before recommending or approving orlistat use, and should advise against its use in patients with these conditions without specialist nephrology input. Any patient actively taking orlistat who presents with signs or symptoms of AKI (rising serum creatinine, oliguria, dependent edema) or nephrolithiasis (flank/groin pain, hematuria, dysuria) should have orlistat discontinued immediately and undergo prompt evaluation including urinalysis with microscopy for calcium oxalate crystalluria, 24-hour urine oxalate, and renal function assessment. Given that injury has been documented as early as 0.7 months into therapy and that OTC status does not guarantee safety, periodic monitoring of renal function (e.g., BMP at baseline and at 1–3 months) should be considered for all patients initiating orlistat, particularly those with obesity-related comorbidities such as hypertension and type 2 diabetes that independently heighten renal vulnerability.